Parlodel Capsules

Evaluate pituitary first. Discontinue if hypertension, severe headache, or CNS toxicity occurs. Evaluate unexplained pleuropulmonary disorders; consider discontinuing if occurs. Risk of retroperitoneal fibrosis (esp. on long-term, high-dose therapy); discontinue if suspected or confirmed. Impulse control/compulsive behaviors (eg, gambling, uncontrolled spending, sexual or other urges) during therapy; consider reducing dose or discontinuing if develop. Psychosis. Dementia. Cardiovascular disease (eg, MI, arrhythmias). Galactose intolerance, severe lactase deficiency, glucose-galactose malabsorption: not recommended. Macroprolactinoma: monitor visual fields. Peptic ulcer. GI bleed. Monitor for tumor expansion; discontinue and consider alternatives if occurs. Risk of neuroleptic malignant-like syndrome with rapid dose reduction, withdrawal, or changes in therapy. Evaluate hematopoietic, cardiovascular (monitor BP), hepatic and renal function periodically. Perform periodic skin exams. Avoid abrupt cessation. Advise to use barrier contraception until ovulation normalizes. Pregnancy (Cat.B); discontinue if occurs in patients with hyperprolactinemia; assess risk vs benefit in other indications (see full labeling). Nursing mothers: not recommended.

Evaluate pituitary first. Discontinue if hypertension, severe headache, or CNS toxicity occurs. Evaluate unexplained pleuropulmonary disorders; consider discontinuing if occurs. Risk of retroperitoneal fibrosis (esp. on long-term, high-dose therapy); discontinue if suspected or confirmed. Impulse control/compulsive behaviors (eg, gambling, uncontrolled spending, sexual or other urges) during therapy; consider reducing dose or discontinuing if develop. Psychosis. Dementia. Cardiovascular disease (eg, MI, arrhythmias). Galactose intolerance, severe lactase deficiency, glucose-galactose malabsorption: not recommended. Macroprolactinoma: monitor visual fields. Peptic ulcer. GI bleed. Monitor for tumor expansion; discontinue and consider alternatives if occurs. Risk of neuroleptic malignant-like syndrome with rapid dose reduction, withdrawal, or changes in therapy. Evaluate hematopoietic, cardiovascular (monitor BP), hepatic and renal function periodically. Perform periodic skin exams. Avoid abrupt cessation. Advise to use barrier contraception until ovulation normalizes. Pregnancy (Cat.B); discontinue if occurs in patients with hyperprolactinemia; assess risk vs benefit in other indications (see full labeling). Nursing mothers: not recommended.